Change in cT1 following interventions in MASLD: A systematic review and meta-analysis

Treatment interventions in MASLD significantly reduce liver cT1 by an average of 57 ms, indicating improved liver health. Fibroblast growth factor analogues, GLP-1 receptor agonists, and FXR agonists showed notable effects, while placebo showed no change. These results inform study design, supporting cT1 as a useful non-invasive treatment response marker.